ETON RSI Chart
Last 7 days
5.5%
Last 30 days
15.3%
Last 90 days
-17.7%
Trailing 12 Months
-0.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 34.3M | 0 | 0 | 0 |
2023 | 24.4M | 29.0M | 32.8M | 31.6M |
2022 | 12.1M | 16.4M | 18.8M | 21.3M |
2021 | 9.1M | 13.3M | 17.6M | 21.8M |
2020 | 558.0K | 578.0K | 0 | 4.8M |
2019 | 385.5K | 607.0K | 582.0K | 959.0K |
2018 | 0 | 0 | 0 | 164.0K |
2017 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 22, 2022 | brynjelsen sean | bought | 21,042 | 2.1042 | 10,000 | chief executive officer |
Nov 17, 2021 | opaleye management inc. | sold | -116,712 | 4.6685 | -25,000 | - |
Nov 16, 2021 | opaleye management inc. | sold | -4,560 | 4.8619 | -938 | - |
Nov 16, 2021 | opaleye management inc. | sold | -55,911 | 4.8619 | -11,500 | - |
Nov 15, 2021 | opaleye management inc. | sold | -2,400 | 4.8016 | -500 | - |
Nov 15, 2021 | opaleye management inc. | sold | -12,004 | 4.8016 | -2,500 | - |
Nov 08, 2021 | opaleye management inc. | sold | -16,234 | 6.101 | -2,661 | - |
Nov 08, 2021 | opaleye management inc. | sold | -305,050 | 6.101 | -50,000 | - |
Nov 05, 2021 | opaleye management inc. | sold | -52,935 | 6.3011 | -8,401 | - |
Nov 05, 2021 | opaleye management inc. | sold | -1,003,770 | 6.3011 | -159,300 | - |
Which funds bought or sold ETON recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 25.23 | 5,828 | 86,543 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | -159,618 | 950,108 | 0.02% |
May 15, 2024 | Royal Bank of Canada | reduced | -70.92 | -9,000 | 3,000 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 445,706 | 445,706 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -99.35 | -21,587 | 120 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -51,284 | 305,261 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | -23.00 | 143 | -% |
May 15, 2024 | AMERIPRISE FINANCIAL INC | sold off | -100 | -709,244 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -122 | - | -% |
May 15, 2024 | Schonfeld Strategic Advisors LLC | added | 66.13 | 107,861 | 363,258 | -% |
Unveiling Eton Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Eton Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Eton Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 8.9% | 7,966,000 | 7,313,000 | 7,028,000 | 11,997,000 | 5,304,000 | 8,498,000 | 3,219,000 | 7,358,000 | 2,176,000 | 6,093,000 | 775,000 | 3,067,000 | 11,897,000 | 5,958,500 | 20,000 | 99,000 | 459,000 | - | - | 500,000 | 82,000 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | 280,000 | 617,000 | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 37.9% | 5,007,000 | 3,630,000 | 4,403,000 | 9,682,000 | 3,346,000 | 6,360,000 | 2,018,000 | 4,613,000 | 1,327,000 | 5,702,500 | 121,000 | 2,893,000 | 10,307,000 | -369,000 | -8,000 | -3,000 | 6,000 | - | - | 500,000 | - |
Operating Expenses | 3.3% | 5,807,000 | 5,623,000 | 4,951,000 | 5,799,000 | 5,880,000 | 5,298,000 | 4,913,000 | 5,953,000 | 6,414,000 | 4,388,500 | 5,968,000 | 5,218,000 | 4,944,000 | 7,051,000 | 4,530,000 | 8,878,000 | 2,662,000 | 5,042,000 | 3,349,000 | 8,054,000 | 2,286,000 |
S&GA Expenses | -100.0% | - | 4,576,000 | 4,336,000 | 4,674,000 | 5,345,000 | 4,354,000 | 4,169,000 | 5,263,000 | 4,796,000 | 3,707,500 | 3,290,000 | 3,228,000 | 4,058,000 | 3,650,000 | 2,921,000 | 2,610,000 | 2,429,000 | 1,624,000 | 1,910,000 | 1,589,000 | 1,184,000 |
R&D Expenses | -37.8% | 651,000 | 1,047,000 | 615,000 | 1,125,000 | 535,000 | 944,000 | 744,000 | 690,000 | 1,618,000 | 681,000 | 2,678,000 | 1,990,000 | 886,000 | 3,401,000 | 1,609,000 | 6,268,000 | 233,000 | 3,418,000 | 1,439,000 | 6,465,000 | - |
EBITDA Margin | 155.2% | 0.09 | 0.03 | 0.12 | 0.05 | -0.16 | -0.31 | -0.34 | -0.59 | -0.92 | -0.03 | -0.53 | -0.72 | - | - | - | - | - | - | - | - | - |
Interest Expenses | -6.9% | 190,000 | 204,000 | 212,000 | 210,000 | 216,000 | 185,000 | 167,000 | 163,000 | 215,000 | 212,000 | 179,000 | 210,000 | 214,000 | 252,000 | 169,000 | 189,000 | - | - | - | - | - |
Income Taxes | -100.0% | - | 247,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 59.6% | -811,000 | -2,009,000 | -579,000 | 4,559,000 | -2,660,000 | 912,000 | -3,045,000 | -1,558,000 | -5,330,000 | 1,039,000 | -6,094,000 | -2,016,000 | 5,116,000 | -7,687,000 | -4,730,000 | -9,049,000 | -2,696,000 | -4,965,000 | -3,249,000 | -7,410,000 | -3,730,000 |
EBT Margin | 255.3% | 0.03 | -0.02 | 0.07 | -0.01 | -0.26 | -0.42 | -0.47 | -0.73 | -1.02 | -0.09 | -0.61 | -0.83 | - | - | - | - | - | - | - | - | - |
Net Income | 64.1% | -811,000 | -2,256,000 | -579,000 | 4,559,000 | -2,660,000 | 912,000 | -3,045,000 | -1,558,000 | -5,330,000 | 1,039,000 | -6,094,000 | -2,016,000 | 5,116,000 | -7,687,000 | -4,730,000 | -9,049,000 | -2,696,000 | -4,965,000 | -3,249,000 | -7,410,000 | -3,730,000 |
Net Income Margin | 190.0% | 0.03 | -0.03 | 0.07 | -0.01 | -0.26 | -0.42 | -0.47 | -0.73 | -1.02 | -0.09 | -0.61 | -0.83 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -742.6% | -2,487,000 | 387,000 | 873,000 | 7,103,000 | -1,548,000 | 2,828,000 | -1,703,000 | 2,450,000 | 1,208,000 | -5,121,000 | -2,952,000 | -413,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -3.0% | 30,794 | 31,740 | 31,526 | 30,932 | 23,928 | 25,030 | 21,520 | 23,046 | 23,196 | 27,465 | 26,606 | 29,906 | 31,186 | 26,319 | 11,395 | 14,559 | 17,241 | 17,072 | 13,507 | 18,244 | 23,017 |
Current Assets | -9.6% | 24,263 | 26,839 | 27,157 | 26,333 | 19,118 | 20,004 | 16,420 | 19,776 | 18,751 | 23,604 | 25,863 | 29,075 | 30,274 | 24,701 | 9,785 | 12,823 | 15,341 | 15,009 | 12,107 | 16,755 | 21,527 |
Cash Equivalents | -22.1% | 16,655 | 21,388 | 22,070 | 21,566 | 14,708 | 16,305 | 13,378 | 17,046 | 15,229 | 14,406 | 22,709 | 25,802 | 25,113 | 21,295 | 7,332 | 10,270 | 12,335 | 12,066 | 11,777 | 14,947 | 19,584 |
Inventory | 154.4% | 2,318 | 911 | 1,051 | 816 | 437 | 557 | 481 | 531 | 510 | 550 | 334 | 1,242 | 1,348 | 1,242 | 1,699 | 1,709 | 1,726 | 380 | - | - | - |
Net PPE | -1.7% | 57.00 | 58.00 | 38.00 | 46.00 | 56.00 | 72.00 | 73.00 | 87.00 | 72.00 | 115 | 134 | 156 | 176 | 811 | 854 | 938 | 1,025 | 1,117 | 1,169 | 1,223 | 1,190 |
Liabilities | -5.9% | 15,300 | 16,263 | 14,634 | 14,207 | 12,687 | 11,952 | 10,339 | 9,804 | 9,813 | 9,835 | 10,946 | 9,170 | 9,631 | 10,656 | 10,007 | 7,528 | 6,621 | 6,522 | 1,159 | 1,545 | 3,775 |
Current Liabilities | -5.8% | 15,300 | 16,241 | 10,393 | 9,588 | 7,494 | 6,461 | 4,661 | 3,812 | 3,482 | 4,558 | 5,360 | 3,106 | 3,199 | 3,794 | 3,219 | 2,739 | 2,051 | 1,963 | 1,107 | 1,459 | 3,656 |
Long Term Debt | - | - | - | 4,197 | 4,553 | 5,107 | 5,384 | 5,678 | 5,992 | 6,331 | 5,262 | 5,550 | 5,856 | 6,183 | 6,532 | 6,496 | 4,587 | 4,570 | 4,540 | - | - | - |
LT Debt, Current | -6.7% | 5,020 | 5,380 | 1,540 | 1,540 | 1,339 | 1,033 | 708 | 364 | 1,033 | 1,418 | 1,092 | 749 | 385 | - | - | - | - | - | - | - | - |
Shareholder's Equity | 0.1% | 15,494 | 15,477 | 16,892 | 16,725 | 11,241 | 13,078 | 11,181 | 13,242 | 13,383 | 17,630 | 15,660 | 20,736 | 21,555 | 15,663 | 1,388 | 7,031 | 10,620 | 10,550 | 12,348 | 16,699 | 19,242 |
Retained Earnings | -0.8% | -104,881 | -104,070 | -101,814 | -101,235 | -105,794 | -103,134 | -104,046 | -101,001 | -99,443 | -94,113 | -95,152 | -89,058 | -87,042 | -92,158 | -84,471 | -77,967 | -73,237 | -64,188 | -61,492 | -56,527 | -53,278 |
Additional Paid-In Capital | 0.7% | 120,349 | 119,521 | 118,680 | 117,934 | 117,009 | 116,187 | 115,202 | 114,218 | 112,801 | 111,718 | 110,787 | 109,769 | 108,573 | 107,797 | 85,838 | 84,977 | 83,836 | 74,720 | 73,822 | 73,208 | 72,502 |
Shares Outstanding | 0% | 25,688 | 25,688 | 25,658 | 25,562 | 25,504 | 25,353 | 25,066 | 25,126 | 25,301 | 24,626 | 25,181 | 24,600 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 84,700 | - | - | - | 51,500 | - | - | - | 108,800 | - | - | - | 64,200 | - | - | - | 96,600 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -739.0% | -2,473 | 387 | 873 | 7,103 | -1,548 | 2,840 | -1,703 | 2,461 | 1,223 | -5,117 | -2,950 | -369 | 3,715 | -7,182 | -5,094 | -2,853 | -7,217 | -3,848 | -3,215 | -4,196 | -6,767 |
Share Based Compensation | 9.5% | 821 | 750 | 730 | 785 | 872 | 886 | 949 | 1,300 | 1,083 | 863 | 1,009 | 836 | 673 | 773 | 724 | 714 | 365 | 501 | 537 | 505 | 345 |
Cashflow From Investing | -142.8% | -1,882 | -775 | - | - | - | -12.00 | -2,000 | -761 | -15.00 | -3,254 | -2.00 | - | - | -44.00 | -2.00 | - | -4.00 | - | - | - | - |
Cashflow From Financing | -28.6% | -378 | -294 | -368 | -246 | -49.00 | 99.00 | 35.00 | 117 | -385 | 68.00 | -141 | 361 | 103 | 21,189 | 2,158 | 788 | 7,490 | 4,921 | 77.00 | 201 | 4.00 |
Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Total net revenues | $ 7,966 | $ 5,304 |
Cost of sales: | ||
Total cost of sales | 2,959 | 1,958 |
Gross profit | 5,007 | 3,346 |
Operating expenses: | ||
Research and development | 651 | 535 |
General and administrative | 5,156 | 5,345 |
Total operating expenses | 5,807 | 5,880 |
Loss from operations | (800) | (2,534) |
Other income (expense): | ||
Other income | 0 | 0 |
Interest expense, net | (11) | (126) |
Total other income (expense) | (11) | (126) |
Loss before income tax expense | (811) | (2,660) |
Income tax expense | 0 | 0 |
Net loss | $ (811) | $ (2,660) |
Net loss per share, basic (in dollars per share) | $ (0.03) | $ (0.1) |
Weighted average number of common shares outstanding, basic (in shares) | 25,763 | 25,525 |
Net loss per share, diluted (in dollars per share) | $ (0.03) | $ (0.1) |
Weighted average number of common shares outstanding, diluted (in shares) | 25,763 | 25,525 |
License [Member] | ||
Revenues: | ||
Total net revenues | $ 0 | $ 0 |
Cost of sales: | ||
Total cost of sales | 0 | 0 |
Product Sales and Royalties [Member] | ||
Revenues: | ||
Total net revenues | 7,966 | 5,304 |
Cost of sales: | ||
Total cost of sales | $ 2,959 | $ 1,958 |
Condensed Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 16,655 | $ 21,388 |
Accounts receivable, net | 4,240 | 3,411 |
Inventories | 2,318 | 911 |
Prepaid expenses and other current assets | 1,050 | 1,129 |
Total current assets | 24,263 | 26,839 |
Property and equipment, net | 57 | 58 |
Intangible assets, net | 6,388 | 4,739 |
Operating Lease, Right-of-Use Asset | 74 | 92 |
Other long-term assets, net | 12 | 12 |
Total assets | 30,794 | 31,740 |
Liabilities, Current [Abstract] | ||
Accounts payable | 2,263 | 1,848 |
Debt, net of unamortized discount | 5,020 | 5,380 |
Accrued Liabilities, Current | 8,017 | 9,013 |
Total current liabilities | 15,300 | 16,241 |
Operating lease liabilities, net of current portion | 0 | 22 |
Total liabilities | 15,300 | 16,263 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity | ||
Common stock, $0.001 par value; 50,000,000 shares authorized; 25,690,562 and 25,688,062 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 26 | 26 |
Additional paid-in capital | 120,349 | 119,521 |
Accumulated deficit | (104,881) | (104,070) |
Total stockholders’ equity | 15,494 | 15,477 |
Total liabilities and stockholders’ equity | $ 30,794 | $ 31,740 |
 | Mr. Sean E. Brynjelsen |
---|---|
 | etonpharma.com |
 | Pharmaceuticals |
 | 28 |